Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGL-3196 in Non-alcoholic Steatohepatitis
NCT02912260Phase 2Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing MGL-3196 with Placebo (2 arms). Primary endpoint: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By MRI-PDFF. Started Oct 2016; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02912260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912260.